Impact of Brokerage Rating on Edwards Lifesciences Corporation(EW)

Many Edwards Lifesciences Corporation(EW) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Edwards Lifesciences Corp was Downgraded by Leerink Partners to Mkt Perform on Feb 2, 2017. Edwards Lifesciences Corp was Upgraded by Guggenheim to Buy on Jan 3, 2017.

Company has reported several Insider transactions to the SEC, on Feb 8, 2017, Donald E Jr Bobo (CVP, Heart Valve Therapy) sold 13,720 shares at 89.63 per share price.On Feb 6, 2017, Kieran Gallahue (director) purchased 3,000 shares at 90.10 per share price.On Jan 17, 2017, Michael A Mussallem (Chairman & CEO) sold 49,100 shares at 97.03 per share price.

Edwards Lifesciences Corp Last issued its quarterly earnings results on Feb 1, 2017. The company reported $0.75 EPS for the quarter, beating the analyst consensus estimate by $ 0.03. Analyst had a consensus of $0.72. The company had revenue of $767.70 million for the quarter, compared to analysts expectations of $758.54 million. The companys revenue was up 14.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.64 EPS.

Edwards Lifesciences Corporation (NYSE:EW) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.53 by 18 Brokerage Firm. 12 Wall Street Firms have rated the stock as a strong buys. 2 stock experts have also suggested a buy rating. 4 Brokerage Firms have advised hold.

Edwards Lifesciences Corporation (NYSE:EW): 17 Analyst have given the stock of Edwards Lifesciences Corporation (NYSE:EW) a near short term price target of $118.41. The standard deviation reading, which is a measure by which the stock price is expected to swing away from the mean estimate, is at $10.57. The higher price target estimate is at $140 while the lower price estimates are fixed at $100.

Edwards Lifesciences Corporation (NYSE:EW) witnessed a decline in the market cap on Tuesday as its shares dropped 0.52% or 0.47 points. After the session commenced at $89.79, the stock reached the higher end at $90.275 while it hit a low of $89.23. With the volume soaring to 1,760,635 shares, the last trade was called at $89.49. The company has a 52-week high of $121.75. The company has a market cap of $19,385 million and there are 216,618,890 shares in outstanding. The 52-week low of the share price is $81.04.

Edwards Lifesciences Corporation provides products and technologies to treat late-stage cardiovascular disease. The Companys products include tissue replacement heart valves, heart valve repair products, hemodynamic monitoring devices, angioscopy equipment, oxygenators, and pharmaceuticals. Edwards Lifesciences Corporation is headquartered in Irvine, California.

Edwards

For any feedback and suggestions contact author at Lisa.Tynan@thefoundersdaily.com

Add Comment